Navigation Links
OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
Date:10/22/2010

n, also referred to as OGX-011.  Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer.  The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer in 2011. OGX-427 has entered Phase 2 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.  More information about OncoGenex is available at www.oncogenex.com.

More information about OncoGenex is available at www.oncogenex.com. OncoGenex' Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, OncoGenex' estimate of the net proceeds of the public offering and the anticipated use of such proceeds.  All statements other than statements of historical fact are statements that could be deemed forward-looking statements.  These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the ability to manage successfully and complete the public offering, the economic and/or market conditions generally, risks relating to OncoGenex' operations and financial performance and the factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Quarterly Report on Form 10-Q for second fiscal quarter of 2010 and the preliminary prospectus supplement to be filed with the SEC.  The Company undertakes no obligation to update the forward-looking statements contained h
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
2. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
3. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
4. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
5. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
6. OncoGenex Reports Second Quarter Financial Results
7. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
8. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
9. OncoGenex Reports First Quarter Financial Results
10. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
11. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Quantum Center at Skolkovo) and Mario Ziman (Masaryk ... of Physics in Bratislava, Slovakia) have found a ... through an amplifier and, conversely, when transmitting a ... an article published in the journal Physical ... particles are considered to be the basis of ...
(Date:7/23/2014)... Last year, Formedix celebrated ... global provider of data management solutions for clinical trials. ... system for electronic data capture (EDC) and clinical data ... study execution tools added TrialMaster to its Transform for ... of Transform for TrialMaster, is being released this week, ...
(Date:7/23/2014)... 23, 2014 DuPont Pioneer announced today ... vice president of Agricultural Biotechnology (ABT), effective July 21, ... served most recently as president, chief executive officer and ... leadership in the seed and crop protection industry to ... E. Schickler , president of DuPont Pioneer. “I am ...
(Date:7/23/2014)... PARK, Calif. , July 23, 2014  Sofinnova ... investment firm, today announced the closing of Sofinnova Venture ... million and in excess of the initial fund target ... helping entrepreneurs build successful biotechnology companies. Consistent with recent ... with promising later stage clinical programs, along with select ...
Breaking Biology Technology:Scientists find way to maintain quantum entanglement in amplified signals 2Scientists find way to maintain quantum entanglement in amplified signals 3Scientists find way to maintain quantum entanglement in amplified signals 4Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 3DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3Sofinnova Raises $500 Million Biotech Venture Fund 2
... IRVINE, California and KARLSRUHE, Germany , June 16, 2010 ,The ... and the US. "Growth requires space" had already been the motto of,the last company ... ... is moving from Campbell to Irvine, California , one,of high-tech industry ...
... N.M. The world,s smallest chess board about ... pea-sized microbarbershop were winners in this year,s design contest ... at Sandia National Laboratories in mid May. The ... Sandia,s microfabrication facility, one of the most advanced in ...
... Raju Kucherlapati , Professor of Genetics at Harvard ... making—will be addressing the Controlled Release Society on the subject of ... , , ... diagnosed with non small cell lung cancer before 2003, there were ...
Cached Biology Technology:joimax(R) Moves Into Larger Premises 2Texas Tech, U of Utah win Sandia microdevice competition 2Texas Tech, U of Utah win Sandia microdevice competition 3Texas Tech, U of Utah win Sandia microdevice competition 4Personalized Treatments for Cancer Are Revolutionizing Patient Care 2Personalized Treatments for Cancer Are Revolutionizing Patient Care 3
(Date:7/23/2014)... , , , , , ... , , , , , ... changing how medical care is delivered could help prevent multiple chronic diseases and extend healthy lifespan. The idea, they argue, would be to target the... ... , , , , ... , , , , , ...
(Date:7/23/2014)... grip is affecting more than the color of people,s lawns. ... heat-loving amoeba commonly found in warm freshwater bodies, such as ... warmer than usual this year. , A 9-year-old Kansas girl ... swimming in several area lakes. The amoeba enters the body ... brain. Nose plugs can lower the odds of this rare ...
(Date:7/23/2014)... planet,s soil releases about 60 billion tons of carbon ... than that released by burning fossil fuels. This happens ... of carbon is balanced by carbon coming into the ... as well as by the underground activities of plant ... rising temperatures increase the rate of soil respiration. As ...
Breaking Biology News(10 mins):Strategy proposed for preventing diseases of aging 2Strategy proposed for preventing diseases of aging 3Strategy proposed for preventing diseases of aging 4Strategy proposed for preventing diseases of aging 5Diseases of another kind 2Climate change and the soil 2
... JOLLA, CA June 1, 2010 In findings that contribute ... by Scripps Research Institute scientists has determined the structure of ... strains of human immunodeficiency virus (HIV), the virus that causes ... advance, online issue of the journal Proceedings of the ...
... release is available in <A HREF=",http://chinese.eurekalert.org/zh/pub_releases/2010-06/sfeb-tio060110.php,">Chinese . ... of Medicine, in New Orleans, LA, have demonstrated ... seed oil ( Nigella sativa ) can suppress ... cell lines, in vitro. Although previous studies ...
... a global leader in forming a proactive response to climate ... adapt to the challenges and opportunities the changing climate presents. ... York City Panel on Climate Change (NPCC) and published in ... , outline the measures the city will take to proactively ...
Cached Biology News:Scripps research scientists determine structure of immune molecule that counteracts HIV strains 2Scripps research scientists determine structure of immune molecule that counteracts HIV strains 3Scripps research scientists determine structure of immune molecule that counteracts HIV strains 4Thymoquinone induced oxidative stress targets highly aggressive prostate cancers 2How New York City is preparing for climate change 2How New York City is preparing for climate change 3
... Pocket Surveyor software provides local instrument ... Surveyor HPLC Systems. The software operates ... popular Windows Pocket PC 2002 O/S ... connect directly to their Surveyor quaternary ...
... separation and fractionation of nucleic-acid ... nuclei from cytosolic proteins A ... greatly facilitating study of low-abundance ... acid binding proteins (e.g., transcription ...
... solution is an isotonic, balanced salt solution. It ... permits the storage of whole blood at refrigerator ... equal volume of blood is collected into a ... mixed. The solution is placed in a refrigerator ...
... fixative useful for routine procedures. Hollandes contains ... and will decalcify small bone specimens. Tissue ... stained successfully with most stains, and the ... blood cell membranes and cosinophil and endocrine ...
Biology Products: